Investigational drug · Phase 2
VT7208
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VT7208"
First trial start
2025
Aug 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VT7208", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "VT7208" as an intervention, largest first.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS PatientsPivotal-lookingRecruiting
Vidya Therapeutics IncIndustry
NCT07085507 · 100 participants (planned) · Start Aug 1, 2025 · Primary completion Oct 30, 2026
Drug: VT7208; Placebo · For: Multiple Sclerosis
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple Sclerosis
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- IMU-838Vidofludimus calciumPhase 33 trials
Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- MRI contrast-enhancing agentsPhase 33 trials
Sanofi · Multiple Sclerosis
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- MRI contrast-enhancing preparationsPhase 32 trials
Sanofi · Multiple Sclerosis
- zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials
Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.